Paris Saclay Seed Fund backed a series A round which will help the biotechnology company expand sales and launch a new product.

France-based DNA quantification company Stilla Technologies has raised €16m ($18m) in a series A round backed by Paris Saclay Seed Fund, a university venture fund formed by University of Paris-Saclay. Illumina Ventures, the corporate venturing arm of genomics technology producer Illumina, led the round, which also featured financial services firm BNP Paribas through its BNP…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.